ViroPharma To Release 2013 First Quarter Financial Results On May 1, 2013

  ViroPharma To Release 2013 First Quarter Financial Results On May 1, 2013

PR Newswire

EXTON, Pa., April 25, 2013

EXTON, Pa., April 25, 2013 /PRNewswire/ -- ViroPharma Incorporated's (Nasdaq:
VPHM) first quarter financial results for 2013 are expected to be released on
Wednesday, May 1, 2013 before the open of the U.S. financial markets.

The company will host a conference call and live audio webcast at 9:00 a.m.
Eastern Time on the same day. During the conference call, ViroPharma
management will discuss the 2013 first quarter financial results, review
clinical data and provide development program updates along with other

The press release and the live webcast of the conference call will be
accessible via ViroPharma's corporate website at
An audio archive will be available at the same address until May 15, 2013. To
participate in the conference call, please dial (800) 874-4559 (domestic) and
(302) 607-2019 (international). After placing the call, please tell the
operator you wish to join the ViroPharma investor conference call.

About ViroPharma Incorporated
ViroPharma Incorporated is an international biopharmaceutical company
committed to developing and commercializing novel solutions for physician
specialists to address unmet medical needs of patients living with diseases
that have few if any clinical therapeutic options.ViroPharma is developing a
portfolio of therapeutics for rare and Orphan diseases including C1 esterase
inhibitor deficiency, cytomegalovirus (CMV), Friedreich's Ataxia, eosinophilic
esophagitis (EoE) and adrenal insufficiency. Our goal is to provide rewarding
careers to employees, to create new standards of care in the way serious
diseases are treated, and to build international partnerships with the
patients, advocates, and health care professionals we serve. ViroPharma's
commercial products address diseases including hereditary angioedema (HAE),
seizures in children and adolescents, adrenal insufficiency and C.
difficile-associated diarrhea (CDAD). For full U.S. prescribing information on
our products, please download the package inserts at; the prescribing information for other
countries can be found at

ViroPharma routinely posts information, including press releases, which may be
important to investors in the investor relations and media sections of our
company's web site, The company encourages investors to
consult these sections for more information on ViroPharma and our business.

SOURCE ViroPharma Incorporated

Contact: ViroPharma Incorporated Contacts: Robert A. Doody, Director, Investor
Relations, Phone (610) 321-6290
Press spacebar to pause and continue. Press esc to stop.